Figures
Setbacks in Alzheimer's research demand new strategies, not surrender
Despite heavy research investments, there has been little if any progress towards an effective treatment for Alzheimer's disease, and leading pharmaceutical company Pfizer recently shuttered its research programs into the disease. On the one-year anniversary of the Special Issue on Dementia, the PLOS Medicine Editors discuss the challenges of addressing a growing population with Alzheimer disease and dementia amidst disappointing news from the pharmaceutical industry. Repeated failures demand new strategies, and an aging population requires action, not surrender.
Image Credit: Daw8ID, Pixabay
Citation: (2018) PLoS Medicine Issue Image | Vol. 15(2) February 2018. PLoS Med 15(2): ev15.i02. https://doi.org/10.1371/image.pmed.v15.i02
Published: February 28, 2018
Copyright: © 2018 Daw8ID, Pixabay. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Despite heavy research investments, there has been little if any progress towards an effective treatment for Alzheimer's disease, and leading pharmaceutical company Pfizer recently shuttered its research programs into the disease. On the one-year anniversary of the Special Issue on Dementia, the PLOS Medicine Editors discuss the challenges of addressing a growing population with Alzheimer disease and dementia amidst disappointing news from the pharmaceutical industry. Repeated failures demand new strategies, and an aging population requires action, not surrender.
Image Credit: Daw8ID, Pixabay